The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Open accessAbstract
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. METHODS: We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with stable disease or an objective response and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. The primary end point was overall survival. RESULTS: Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher survival rates in the ipilimumab-dacarbazine group at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P<0.001). Grade 3 or 4 adverse events occurred in 56.3% of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P<0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipilimumab-dacarbazine group. CONCLUSIONS: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, approximately 20% of patients who received ipilimumab achieved long-term survival greater than three years, with survival of 10 years noted for some patients (38,42).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [38]
In the citing paper
“Ipilimumab (anti-CTLA4) was the first ICT to gain FDA approval in 2011 for the treatment of metastatic melanoma, on the basis of phase III trials demonstrating improvements in overall survival compared with vaccine or chemotherapy (37,38).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [38]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Eguchi, S., Takatsuki, M., Soyama, A., Hara, T., Hidaka, M., Muraoka, I., & Kanematsu, T. (2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
Self-citationWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Mokyr MB, 1998, Cancer Res, 58, 5301
Cited by
Sorted by citations
Items 401–500 of 1,022
Molecular and histopathology directed therapy for advanced bladder cancer
Alifrangis, C., McGovern, U., Freeman, A., Powles, T. B., & Linch, M. D. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0208-0 · Cited by 201
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Management of conjunctival malignant melanoma: a review and update
Wong, J. R., Nanji, A., Galor, A., & Karp, C. L. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.921119 · Cited by 198
Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology
Salomon, B. L., Leclerc, M., Tosello, J., Ronin, É., Piaggio, E., & Cohen, J. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00444 · Cited by 198
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
del Valle, A. S., Anel, A., Naval, J., & Marzo, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00050 · Cited by 199
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S. M., Nimeiri, H. S., Fought, A. J., Benson, A. B., & Mulcahy, M. F. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 200
High endothelial venules (HEVs) in human melanoma lesions
Martinet, L., Guellec, S. L., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 206
Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S. S., AMATRUDA, T. T., Bines, S. D., Clark, J. I., Curti, B. D., Ernstoff, M. S., Gajewski, T. F., et al. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.153 · Cited by 199
Self-citationPark, Y., Kuen, D., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 198
Zimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M. S., Heinzerling, L., Krackhardt, A. M., Loquai, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.009 · Cited by 193
Patel, K. R., Shoukat, S., Oliver, D. E., Chowdhary, M., Rizzo, M., Lawson, D. H., Khosa, F., Liu, Y., & Khan, M. K. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000199 · Cited by 192
Reprogramming the immunological microenvironment through radiation and targeting Axl
Aguilera, T. A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M. S., Hui, A. B., Stehr, H., von Eyben, R., Jiang, D., Ellies, L. G., et al. (2016) · Nature Communications · doi:10.1038/ncomms13898 · Cited by 197
Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0328-8 · Cited by 190
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 202
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
Quezada, S. A., & Peggs, K. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.117 · Cited by 192
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 194
Mucosal melanoma of the head and neck
Ascierto, P. A., Accorona, R., Botti, G., Farina, D., Fossati, P., Gatta, G., Gogas, H. J., Lombardi, D., Maroldi, R., Nicolai, P., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.019 · Cited by 188
Hamid, O., Puzanov, I. J., Dummer, R., Schachter, J., DAUD, A. I., Schadendorf, D., Blank, C. U., Cranmer, L. D., Robert, C., Pavlick, A. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.022 · Cited by 190
Self-citationIpilimumab in patients with cancer and the management of dermatologic adverse events
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., BUSAM, K. J., & Hauschild, A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.02.035 · Cited by 186
Self-citationIn situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Hammerich, L., Binder, A. F., & Brody, J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.016 · Cited by 188
Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber, H., Sapra, P., Loganzo, F., & May, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.008 · Cited by 188
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
de Coaña, Y. P., Choudhury, A., & Kiessling, R. W. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.005 · Cited by 187
New drugs in melanoma: It’s a whole new world
Eggermont, A. M. M., & Robert, C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.052 · Cited by 185
Self-citationTripp, M. K., Watson, M., Balk, S. J., Swetter, S. M., & Gershenwald, J. E. (2016) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21352 · Cited by 191
Wilson, M. A., & Schuchter, L. M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_8 · Cited by 191
(ECIL), O. B. O. T. E. C. O. I. I. L., Maschmeyer, G., Greef, J. D., Mellinghoff, S. C., Nosari, A., Thiébaut, A., Bergeron, A., Franquet, T., Blijlevens, N. M. A., & Maertens, J. A. (2019) · Leukemia · doi:10.1038/s41375-019-0388-x · Cited by 188
Feng, Y., Roy, A., Masson, E., Chen, T., Humphrey, R. W., & Weber, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3243 · Cited by 187
Self-citationPulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza‐Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182
Shahabi, V., Berman, D., Chasalow, S. D., Wang, L., Tsuchihashi, Z., Hu, B., Panting, L., Jure‐Kunkel, M., & Ji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-75 · Cited by 186
Melanoma treatment: from conventional to nanotechnology
Mishra, H., Mishra, P. K., Ekielski, A., Jaggi, M., Iqbal, Z., & Talegaonkar, S. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2726-1 · Cited by 189
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
Self-citationRheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
Lidar, M., Giat, E., Garelick, D., Horowitz, Y., Amital, H., Steinberg-Silman, Y., Schachter, J., Shapira-Frommer, R., & Markel, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.003 · Cited by 180
Which drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Barbee, M. S., Ogunniyi, A., Horvat, T. Z., & Dang, T.-O. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015586218 · Cited by 184
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X., & Li, B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490025 · Cited by 182
Immunology beats cancer: a blueprint for successful translation
Pardoll, D. M. (2012) · Nature Immunology · doi:10.1038/ni.2392 · Cited by 182
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
Maki, R. G., Jungbluth, A. A., Gnjatic, S., Schwartz, G. K., D’Adamo, D. R., Keohan, M. L., Wagner, M. J., Scheu, K., Chiu, R., Ritter, E., et al. (2013) · Sarcoma · doi:10.1155/2013/168145 · Cited by 178
Howard, J. H., Thompson, J. F., Mozzillo, N., Nieweg, O. E., Hoekstra, H. J., Roses, D. F., Sondak, V. K., Reintgen, D. S., Kashani–Sabet, M., Karakousis, C. P., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2398-z · Cited by 178
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P. M., & Sekulić, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 178
Immunotherapy advances for glioblastoma
Reardon, D. A., Freeman, G. J., Wu, C. J., Chiocca, E. A., Wucherpfennig, K. W., Wen, P. Y., Fritsch, E. F., Curry, W. T., Sampson, J. H., & Dranoff, G. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou212 · Cited by 181
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E. L., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 181
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Yshii, L., Hohlfeld, R., & Liblau, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.144 · Cited by 178
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 178
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Morrissey, K., Yuraszeck, T. M., Li, C., Zhang, Y., & Kasichayanula, S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12391 · Cited by 181
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033635 · Cited by 175
Self-citationWolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K. M., Cykowski, L., de Pril, V., Humphrey, R. W., & Lebbé, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt161 · Cited by 175
Self-citationDevelopment of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 179
Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174
Sideras, K., Braat, H., Kwekkeboom, J., van Eijck, C. H. J., Peppelenbosch, M. P., Sleijfer, S., & Bruno, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.005 · Cited by 180
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales‐Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 174
Self-citationSurvival of patients with advanced metastatic melanoma: The impact of novel therapies
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P. C., McArthur, G. A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.013 · Cited by 179
Self-citationBoussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., Assi, A., Tatsi, K., Pavlidis, N. A., & Pentheroudakis, G. E. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.006 · Cited by 175
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
Ito, K., Teng, R. S. Y., Schöder, H. M., Humm, J. L., Ni, A., Michaud, L., Nakajima, R., Yamashita, R., Wolchok, J. D., & Weber, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213652 · Cited by 174
Self-citationMonoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 182
Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 175
Diagnostic and prognostic biomarkers in melanoma.
Weinstein, D. M., Leininger, J., Hamby, C. V., & Safai, B. (2014) · PubMed Central · Cited by 172
Sanmamed, M. F., Rodríguez, I., Schalper, K. A., Oñate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., Morales‐Kastresana, A., Labiano, S., Perez‐Gracia, J. L., Martín‐Algarra, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3510 · Cited by 180
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Emens, L. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.147 · Cited by 172
Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Johnson, D. B., Lovly, C. M., Flavin, M., Panageas, K. S., Ayers, G. D., Zhao, Z., Iams, W. T., Colgan, M. N., DeNoble, S., Terry, C. R., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0207 · Cited by 172
Ellebæk, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172
Inozume, T., Yaguchi, T., Furuta, J., Harada, K., Kawakami, Y., & Shimada, S. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.404 · Cited by 172
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 171
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179
Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity
Carvajal, R. D., Spencer, S. A., & Lydiatt, W. M. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0034 · Cited by 171
Aarntzen, E. H. J. G., de Vries, I. J. M., Lesterhuis, W. J., Schuurhuis, D. H., Jacobs, J. F. M., Bol, K. F., Schreibelt, G., Mus, R. D. M., de Wilt, J. H. W., Haanen, J. B. A. G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1127 · Cited by 170
Loss of PBRM1 expression is associated with renal cell carcinoma progression
Pawłowski, R., Mühl, S. M., Sulser, T., Krek, W., Moch, H., & Schraml, P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27822 · Cited by 170
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 171
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 171
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez‐Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 172
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 178
Why is melanoma so metastatic?
Braeuer, R. R., Watson, I. R., Wu, C., Mobley, A. K., Kamiya, T., Shoshan, E., & Bar‐Eli, M. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12172 · Cited by 174
Page, D. B., Yuan, J. D., Redmond, D., Wen, Y. H., Durack, J. C., Emerson, R., Solomon, S. B., Dong, Z., Wong, P., Comstock, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0013 · Cited by 168
Self-citationAdvances in Cancer Immunotherapy in Solid Tumors
Menon, S. P., Shin, S. J., & Dy, G. K. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 170
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 169
Galanis, E., Markovic, S. N., Suman, V. J., Nuovo, G. J., Vile, R. G., Kottke, T. J., Nevala, W. K., Thompson, M. A., Lewis, J. E., Rumilla, K. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.146 · Cited by 167
Combination immunotherapy approaches
Drake, C. G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds262 · Cited by 171
Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 172
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M. M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D. E., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 168
Statistical issues and challenges in immuno-oncology
Chen, T. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-18 · Cited by 167
Self-citationIpilimumab for Patients With Advanced Mucosal Melanoma
Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N. H., Panageas, K. S., Lawrence, D. P., Ibrahim, N., Flaherty, K. T., Sullivan, R. J., Ott, P. A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0464 · Cited by 165
Self-citationImmune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
Kyi, C., & Postow, M. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0002 · Cited by 166
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Melanoma: New Insights and New Therapies
Nikolaou, V. A., Stratigos, A., Flaherty, K. T., & Tsao, H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.421 · Cited by 164
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 166
Ascierto, P. A., Simeone, E., Chiarion‐Sileni, V., Pigozzo, J., Maio, M., Altomonte, M., Vecchio, M. D., Guardo, L. D., Marchetti, P., Ridolfi, R., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-116 · Cited by 163
Self-citationAbdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Moskovitz, J. M., Moy, J. D., & Ferris, R. L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0654-5 · Cited by 164
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C., Yelensky, R., Jooss, K. U., & Chan, T. A.-T. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 164
Huang, Q., Liang, J., Chen, Q., Jin, X., Niu, M., Dong, C., & Zhang, X. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101911 · Cited by 162
Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes
Barker, C. A., & Postow, M. A. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.08.035 · Cited by 161
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., Ottaviano, V., & Queirolo, P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s39096 · Cited by 163
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management
Postow, M. A., Hamid, O., & Carvajal, R. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0244-x · Cited by 161
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E. W., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 165
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Herzberg, B., Campo, M. J., & Gainor, J. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0189 · Cited by 165
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 162
Hannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaı̈b, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 166
Self-citationTargeted Therapy and Immunotherapy for Melanoma in Japan
Namikawa, K., & Yamazaki, N. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0607-8 · Cited by 162
Su, Q., Zhu, E. C., Wu, J., Li, T., Hou, Y., Wang, D., & Gao, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 162
Metadata
- Authors
- Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T.-T., Humphrey, R., Hoos, A., & Wolchok, J. D.
- Affiliations
- Institut Gustave Roussy (FR)
- Hôpital Lyon Sud (FR)
- Dnipro State Medical University (UA)
- Angeles Clinic and Research Institute (US)
- Moffitt Cancer Center (US)
- Cliniques Universitaires Saint-Luc (BE)
- European Institute of Oncology (IT)
- Hôpital de la Timone (FR)
- Mid Essex Hospital Services NHS Trust (GB)
- Oncology Specialists (US)
- University of Siena (IT)
- Christian-Albrechts-Universität zu Kiel (DE)
- Hadassah Medical Center (IL)
- Medical University of Vienna (AT)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2517-2526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2123363005
- Cited by
- 4,496
- References
- 29
- Citations by year
- 2026: 58 · 2025: 99 · 2024: 148 · 2023: 173 · 2022: 213 · 2021: 249 · 2020: 289 · 2019: 283 · 2018: 374 · 2017: 415 · 2016: 466 · 2015: 476 · 2014: 400 · 2013: 392 · 2012: 346
- FWCI
- 195.50
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, dacarbazine, metastatic melanoma, combination immunotherapy, CTLA-4 blockade, overall survival, adverse events, liver dysfunction, maintenance therapy, immune-related adverse events, immune checkpoint inhibitors, progression-free survival
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Double-Blind Method, Female, Humans, Liver Function Tests, Male, Melanoma, Middle Aged, Proportional Hazards Models, Disease Progression, Antineoplastic Agents, Alkylating, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
